Skip to content
10-Q

Quarterly Report

Immunic, Inc. IMUX

0001280776-26-000010

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 13.62M sh
Shares Diluted Q1 2026 · Mar 31, 2026 30.14M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 10.13M sh
Capex Q1 2026 · Mar 31, 2026 $2K
Capex Q1 2026 · Mar 31, 2025 $47K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$17.3M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$21.78M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $186.63M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $15.48M
Stockholders Equity Q1 2026 · Mar 31, 2026 $151.23M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$6.67M
Stockholders Equity Q1 2026 · Mar 31, 2025 −$5.29M
Stockholders Equity Q1 2026 · Dec 31, 2024 $18.43M
Current Liabilities Q1 2026 · Mar 31, 2026 $38.36M
Current Liabilities Q1 2026 · Dec 31, 2025 $30.62M
Total Liabilities Q1 2026 · Mar 31, 2026 $38.51M
Total Liabilities Q1 2026 · Dec 31, 2025 $30.73M
Current Assets Q1 2026 · Mar 31, 2026 $188.76M
Current Assets Q1 2026 · Dec 31, 2025 $22.87M
Total Assets Q1 2026 · Mar 31, 2026 $189.74M
Total Assets Q1 2026 · Dec 31, 2025 $24.05M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.08
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.51
Eps Basic Q1 2026 · Mar 31, 2026 −$1.08
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.51
Sga Expense Q1 2026 · Mar 31, 2026 $7.61M
Sga Expense Q1 2026 · Mar 31, 2025 $5.29M
Rd Expense Q1 2026 · Mar 31, 2026 $25.63M
Rd Expense Q1 2026 · Mar 31, 2025 $21.53M
Net Income Q1 2026 · Mar 31, 2026 −$32.59M
Net Income Q1 2026 · Mar 31, 2025 −$25.47M
Operating Income Q1 2026 · Mar 31, 2026 −$33.24M
Operating Income Q1 2026 · Mar 31, 2025 −$26.83M